Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Calcium voltage-gated channel auxiliary subunit gamma 5 (CACNG5) is a type II transmembrane protein that belongs to the family of gamma subunits of voltage-dependent calcium channels and is also classified as a transmembrane AMPA receptor regulatory protein (TARP)[1][5][8]. CACNG5 regulates AMPA-type glutamate receptors (AMPARs) by accelerating their rates of activation, deactivation, and desensitization, and it shows specificity for certain AMPAR subunits such as GRIA1, GRIA4, and the long isoform of GRIA2[5][1][8]. It stabilizes voltage-gated calcium channels in an inactivated state, thus modulating neuronal excitability[8][1]. CACNG5 is involved in neurotransmitter receptor internalization and trafficking and is genetically associated with increased risk of psychiatric disorders, including bipolar disorder and schizophrenia[1][6]. There are currently no clinically approved drugs that specifically target CACNG5.
Modulation of AMPA receptor trafficking and gating; Modulation of voltage-dependent calcium channel properties
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Calcium voltage-gated channel auxiliary subunit gamma 5 (CACNG5).